Hepcidin in chronic kidney disease anemia

Vitamins and Hormones
Alice Santos-SilvaLuís Belo

Abstract

Chronic kidney disease (CKD) is associated with several complications that worsen with progression of disease; anemia, disturbances in iron metabolism and inflammation are common features. Inflammatory response starts early, releasing pro-inflammatory cytokines, acute phase reactants and hepcidin. Hepcidin production is modulated by several factors, as hypoxia/anemia, erythropoietin and erythropoiesis products, transferrin saturation (TSAT) and liver iron levels, which are altered in CKD. Treatment of CKD anemia is based on pharmaceutical intervention, with erythropoietic stimulating agents and/or iron supplementation; however, in spite of the erythropoietic benefits, this therapy, on a regular basis, involves risks, namely iron overload. To overcome these risks, some therapeutic approaches are under study to target CKD anemia. Considering the actual alerts about risk of iron overload in dialysis patients, inhibition of hepcidin, the central key player in iron homeostasis, could be a pivotal strategy in the management of CKD anemia.

Citations

Jun 20, 2020·Blood·Aryeh ShanderLawrence T Goodnough
Jul 3, 2019·Journal of Clinical Medicine·Mette M BergerNawfel Ben-Hamouda
Jan 28, 2021·International Journal of Molecular Sciences·Kuo-Hua LeeDer-Cherng Tarng
Jul 6, 2021·Frontiers in Medicine·Zhong ZhongHaiping Mao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
Andrea IcardiMario Cozzolino
Acta Physiologica Hungarica
J BallaGy Balla
Nihon rinsho. Japanese journal of clinical medicine
Masayoshi KobuneYoshiro Niitsu
© 2022 Meta ULC. All rights reserved